Damora Therapeutics, Inc. (DMRA) Earnings History
Net Loss8 years of earnings data (2018–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Damora Therapeutics, Inc. (DMRA) Earnings Overview
As of November 18, 2026, Damora Therapeutics, Inc. (DMRA) reported trailing twelve-month net income of -$292M, reflecting -725.6% year-over-year growth. The company earned $-17.82 per diluted share over the past four quarters.
Looking at the long-term picture, DMRA's historical earnings data spans multiple years. The company achieved its highest annual net income of -$16M in fiscal 2018.
Damora Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including GALT (-$23M net income), IMVT (-$509M net income), TGTX ($106M net income, 72.6% margin), DMRA has comparable earnings metrics. Compare DMRA vs GALT →
DMRA Earnings vs Peers
Earnings metrics vs comparable public companies
DMRA Historical Earnings Data (2018–2025)
8 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$210M | -878.8% | -$211M | $-152.99 | - | - |
| 2024 | -$21M | +44.1% | -$17M | $-18.53 | - | - |
| 2023 | -$38M | +37.8% | -$36M | $-36.08 | - | - |
| 2022 | -$62M | -19.1% | -$61M | $-60.63 | - | - |
| 2021 | -$52M | -48.6% | -$52M | $-51.22 | - | - |
| 2020 | -$35M | +4.6% | -$34M | $-34.48 | - | - |
| 2019 | -$37M | -130.1% | -$39M | $-41.35 | - | - |
| 2018 | -$16M | - | -$13M | $-18.68 | - | - |
Download Data
Export DMRA earnings history in CSV or JSON format
Free sign-in required to download data
DMRA Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
8+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
DMRA — Frequently Asked Questions
Quick answers to the most common questions about buying DMRA stock.
What is DMRA earnings per share (EPS)?
DMRA trailing twelve-month (TTM) diluted EPS is $-17.82, reflecting -725.6% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2018 to 2025 is available in the table on this page.
What is Damora Therapeutics, Inc.'s net income?
Damora Therapeutics, Inc. (DMRA) trailing twelve-month net income is $-292M as of 2025. Earnings declined -725.6% year-over-year.
Is DMRA profitable?
DMRA is not currently profitable on a TTM basis, reporting a net loss of $-292M. Net margin is N/A. Investors should monitor for a return to profitability.
What is DMRA's earnings growth rate?
DMRA compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2018 to 2025.
What are DMRA's profit margins?
Damora Therapeutics, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -164.7%.
Is DMRA growing earnings?
DMRA earnings are declining — EPS fell -725.6% year-over-year. TTM net income dropped to $-292M. This contrasts with the 5-year CAGR of N/A.
What was DMRA's best earnings year?
Damora Therapeutics, Inc.'s highest annual net income on record is $-16M, achieved in fiscal year 2018. Earnings history on this page spans 2018 to 2025 and includes all annual and quarterly figures.
What were DMRA's earnings last quarter?
DMRA's most recent reported quarter was Q3 2026. Net income was $-32M with diluted EPS of $-0.40. For a full breakdown of all quarters, see the quarterly earnings table on this page.